Robert F. Kennedy Jr. has permitted unapproved peptides to be sold without rigorous safety testing, despite expert warnings. Medical professionals and researchers caution that there is insufficient evidence to support the safety and efficacy of these substances.
The decision has raised concerns among public health advocates who emphasize the need for proper regulatory oversight. Peptides, often marketed for anti-aging or performance enhancement, are not required to undergo the same approval process as pharmaceuticals. This shift in policy could expose consumers to potential health risks.
The move reflects a broader debate over supplement regulation and the balance between consumer access and public protection.
Source: Wall Street Journal US Business · Summarized by HeadlinesBriefing